Kinase inhibitors in the treatment of renal cell carcinoma

Critical Reviews in Oncology/Hematology

Volumn 60, Issue 3, 2006, Pages 216-226

  Larkin, James M G ^a   Eisen, Tim ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Kinase inhibition; Metastatic; Renal cell carcinoma; Systemic therapy; Targeted drugs

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; AG 013736; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; AXITINIB; BEVACIZUMAB; CETUXIMAB; ERLOTINIB; GEFITINIB; IMATINIB; INTERLEUKIN 2; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MEDROXYPROGESTERONE ACETATE; PHOSPHOTRANSFERASE INHIBITOR; PLATELET DERIVED GROWTH FACTOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SEMAXANIB; SORAFENIB; STEM CELL FACTOR RECEPTOR; SUNITINIB; TEMSIROLIMUS; TRASTUZUMAB; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANEMIA; ANGIOGENESIS; ANOREXIA; CANCER IMMUNOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CHEMOTHERAPY INDUCED EMESIS; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONSTIPATION; DEHYDRATION; DIARRHEA; DISEASE FREE SURVIVAL; DRUG ERUPTION; DRUG INDUCED HEADACHE; DYSPEPSIA; ENZYME INHIBITION; FATIGUE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL STROMAL TUMOR; HOARSENESS; HUMAN; HYPERGLYCEMIA; HYPERPHOSPHATEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INFECTION; KIDNEY CARCINOMA; LEUKOPENIA; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; METASTASIS; NAUSEA; NAUSEA AND VOMITING; NONHUMAN; PATHOPHYSIOLOGY; PROTEINURIA; REVIEW; SIDE EFFECT; SKIN MANIFESTATION; STOMATITIS; WEIGHT REDUCTION;

CARCINOMA, RENAL CELL; HUMANS; KIDNEY NEOPLASMS; PROTEIN KINASE INHIBITORS;

EID: 33750711391     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2006.06.008     Document Type: Review

References (95)

1. Landis S.H., et al. Cancer statistics, 1999. CA Cancer J Clin 49 1 (1999) 8-31 1
2. Parkin D.M., Pisani P., and Ferlay J. Global cancer statistics. CA Cancer J Clin 49 1 (1999) 33-64 1
3. Ficarra V., et al. Multiinstitutional European validation of the 2002 TNM staging system in conventional and papillary localized renal cell carcinoma. Cancer 104 5 (2005) 968-974
4. Cheville J.C., et al. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol 27 5 (2003) 612-624
5. Beck S.D., et al. Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma. Ann Surg Oncol 11 1 (2004) 71-77
6. Motzer R.J., et al. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol 20 9 (2002) 2376-2381
7. Latif F., et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260 5112 (1993) 1317-1320
8. Kim W.Y., and Kaelin W.G. Role of VHL gene mutation in human cancer. J Clin Oncol 22 24 (2004) 4991-5004
9. Brauch H., et al. VHL alterations in human clear cell renal cell carcinoma: association with advanced tumor stage and a novel hot spot mutation. Cancer Res 60 7 (2000) 1942-1948
10. Kondo K., et al. Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: relationship to clinicopathological parameters. Genes Chromosomes Cancer 34 1 (2002) 58-68
11. Yao M., et al. VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma. J Natl Cancer Inst 94 20 (2002) 1569-1575
12. Herman J.G., et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci USA 91 21 (1994) 9700-9704
13. Dulaimi E., et al. Promoter hypermethylation profile of kidney cancer. Clin Cancer Res 10 12 Pt 1 (2004) 3972-3979
14. Clifford S.C., et al. Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis. Genes Chromosomes Cancer 22 3 (1998) 200-209
15. Ohh M., et al. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol 2 7 (2000) 423-427
16. Yang J.C., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349 5 (2003) 427-434
17. Hainsworth J.D., et al. Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J Clin Oncol 23 31 (2005) 7889-7896
18. Turner K.J., et al. Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation. Cancer Res 62 10 (2002) 2957-2961
19. Selli C., et al. Stratification of risk factors in renal cell carcinoma. Cancer 52 5 (1983) 899-903
20. Medical Research Council Renal Cancer Collaborators. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Lancet 353 9146 (1999) 14-17
21. Motzer R.J., Bacik J., and Mazumdar M. Prognostic factors for survival of patients with stage IV renal cell carcinoma: memorial sloan-kettering cancer center experience. Clin Cancer Res 10 18 Pt 2 (2004) 6302S-6303S
22. Motzer R.J., et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 22 3 (2004) 454-463
23. Mickisch G.H., et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 358 9286 (2001) 966-970
24. Flanigan R.C., et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 345 23 (2001) 1655-1659
25. Yagoda A., and Bander N.H. Failure of cytotoxic chemotherapy, 1983-1998, and the emerging role of monoclonal antibodies for renal cancer. Urol Int 44 6 (1989) 338-345
26. Harris D.T. Hormonal therapy and chemotherapy of renal-cell carcinoma. Semin Oncol 10 4 (1983) 422-430
27. Horoszewicz J.S., and Murphy G.P. An assessment of the current use of human interferons in therapy of urological cancers. J Urol 142 5 (1989) 1173-1180
28. Pyrhonen S., et al. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 17 9 (1999) 2859-2867
29. Coppin C., et al. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 1 (2005) CD001425
30. Negrier S., et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. N Engl J Med 338 18 (1998) 1272-1278
31. Rosenberg S.A., et al. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann Surg 228 3 (1998) 307-319
32. McDermott D.F., et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 23 1 (2005) 133-141
33. Atkins M., et al. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res 11 10 (2005) 3714-3721
34. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 103 2 (2000) 211-225
35. Pao W., et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101 36 (2004) 13306-13311
36. Sordella R., et al. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305 5687 (2004) 1163-1167
37. Ferrara N., Gerber H.P., and LeCouter J. The biology of VEGF and its receptors. Nat Med 9 6 (2003) 669-676
38. Ferrara N., et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3 5 (2004) 391-400
39. Druker B.J., et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344 14 (2001) 1031-1037
40. van Oosterom A.T., et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 358 9291 (2001) 1421-1423
41. Herbst R.S., et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol 22 5 (2004) 785-794
42. Giaccone G., et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol 22 5 (2004) 777-784
43. Kris M.G., et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290 16 (2003) 2149-2158
44. Shepherd F.A., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353 2 (2005) 123-132
45. Paez J.G., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304 5676 (2004) 1497-1500
46. Lynch T.J., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350 21 (2004) 2129-2139
47. Uhlman D.L., et al. Epidermal growth factor receptor and transforming growth factor alpha expression in papillary and nonpapillary renal cell carcinoma: correlation with metastatic behavior and prognosis. Clin Cancer Res 1 8 (1995) 913-920
48. Motzer R.J., et al. Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma. Invest New Drugs 21 1 (2003) 99-101
49. Dawson N.A., et al. A phase II trial of gefitinib (Iressa ZD1839) in stage IV and recurrent renal cell carcinoma. Clin Cancer Res 10 23 (2004) 7812-7819
50. Drucker B., et al. Phase II trial of ZD1839 (IRESSA) in patients with advanced renal cell carcinoma. Invest New Drugs 21 3 (2003) 341-345
51. Jermann M., et al. A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma. Cancer Chemother Pharmacol (2005) 1-7
52. Therasse P., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 3 (2000) 205-216
53. Kuenen B.C., et al. Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma. Clin Cancer Res 9 5 (2003) 1648-1655
54. Lara Jr. P.N., et al. SU5416 plus interferon alpha in advanced renal cell carcinoma: a phase II California Cancer Consortium Study with biological and imaging correlates of angiogenesis inhibition. Clin Cancer Res 9 13 (2003) 4772-4781
55. Davis D.W., et al. Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668. Clin Cancer Res 11 2 Pt 1 (2005) 678-689
56. Mendel D.B., et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9 1 (2003) 327-337
57. O'Farrell A.M., et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 101 9 (2003) 3597-3605
58. Faivre S., et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24 1 (2006) 25-35
59. Motzer R.J., et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24 1 (2006) 16-24
60. Rugo H.S., et al. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol 23 24 (2005) 5474-5483
61. Marais R., et al. Differential regulation of Raf-1, A-Raf, and B-Raf by oncogenic ras and tyrosine kinases. J Biol Chem 272 7 (1997) 4378-4383
62. Sridhar S.S., Hedley D., and Siu L.L. Raf kinase as a target for anticancer therapeutics. Mol Cancer Ther 4 4 (2005) 677-685
63. Fujita J., et al. Activated H-ras oncogenes in human kidney tumors. Cancer Res 48 18 (1988) 5251-5255
64. Oka H., et al. Constitutive activation of mitogen-activated protein (MAP) kinases in human renal cell carcinoma. Cancer Res 55 18 (1995) 4182-4187
65. Davies H., et al. Mutations of the BRAF gene in human cancer. Nature 417 6892 (2002) 949-954
66. Nagy A., Balint I., and Kovacs G. Frequent allelic changes at chromosome 7q34 but lack of mutation of the BRAF in papillary renal cell tumors. Int J Cancer 106 6 (2003) 980-981
67. Wilhelm S.M., et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64 19 (2004) 7099-7109
68. Awada A., et al. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer 92 10 (2005) 1855-1861
69. Hirte HW, et al. Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann Oncol; 2005.
70. Strumberg D., et al. Results of phase I pharmacokinetic and pharmacodynamic studies of the Raf kinase inhibitor BAY 43-9006 in patients with solid tumors. Int J Clin Pharmacol Ther 40 12 (2002) 580-581
71. Strumberg D., et al. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 23 5 (2005) 965-972
72. Rosner G.L., Stadler W., and Ratain M.J. Randomized discontinuation design: application to cytostatic antineoplastic agents. J Clin Oncol 20 22 (2002) 4478-4484
73. Stadler W.M., et al. Successful implementation of the randomized discontinuation trial design: an application to the study of the putative antiangiogenic agent carboxyaminoimidazole in renal cell carcinoma-CALGB 69901. J Clin Oncol 23 16 (2005) 3726-3732
74. Hudson C.C., et al. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol 22 20 (2002) 7004-7014
75. Shin Lee J., et al. Expression of PTEN in renal cell carcinoma and its relation to tumor behavior and growth. J Surg Oncol 84 3 (2003) 166-172
76. Hara S., et al. Akt activation in renal cell carcinoma: contribution of a decreased PTEN expression and the induction of apoptosis by an Akt inhibitor. Ann Oncol 16 6 (2005) 928-933
77. Vignot S., et al. mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 16 4 (2005) 525-537
78. Atkins M.B., et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22 5 (2004) 909-918
79. Wolff N.C., et al. The CNS is a sanctuary for leukemic cells in mice receiving imatinib mesylate for Bcr/Abl-induced leukemia. Blood 101 12 (2003) 5010-5013
80. Leis J.F., et al. Central nervous system failure in patients with chronic myelogenous leukemia lymphoid blast crisis and Philadelphia chromosome positive acute lymphoblastic leukemia treated with imatinib (STI-571). Leuk Lymphoma 45 4 (2004) 695-698
81. Bujassoum S., Rifkind J., and Lipton J.H. Isolated central nervous system relapse in lymphoid blast crisis chronic myeloid leukemia and acute lymphoblastic leukemia in patients on imatinib therapy. Leuk Lymphoma 45 2 (2004) 401-403
82. Takayama N., et al. Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome-positive acute lymphoblastic leukaemia due to poor penetration into cerebrospinal fluid. Br J Haematol 119 1 (2002) 106-118
83. le Coutre P., et al. Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588. Cancer Chemother Pharmacol 53 4 (2004) 313-323
84. Dai H., et al. Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux. J Pharmacol Exp Ther 304 3 (2003) 1085-1192
85. Larkin J.M., and Gore M.E. The MRC randomised-controlled trial of interferon-alpha, interleukin-2 and 5-fluorouracil vs. interferon-alpha alone in patients with advanced renal cell carcinoma (RE04): rationale and progress. Clin Oncol (R Coll Radiol) 17 5 (2005) 319-321
86. Kosari F., et al. Clear cell renal cell carcinoma: gene expression analyses identify a potential signature for tumor aggressiveness. Clin Cancer Res 11 14 (2005) 5128-5139
87. Yang X.J., et al. A molecular classification of papillary renal cell carcinoma. Cancer Res 65 13 (2005) 5628-5637
88. Zalcberg J.R., et al. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer 41 12 (2005) 1751-1757
89. Heinrich M.C., et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21 23 (2003) 4342-4349
90. Clark J.I., et al. Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. J Clin Oncol 21 16 (2003) 3133-3140
91. Messing E.M., et al. Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. J Clin Oncol 21 7 (2003) 1214-1222
92. Pizzocaro G., et al. Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study. J Clin Oncol 19 2 (2001) 425-431
93. Atzpodien J., et al. Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). Br J Cancer 92 5 (2005) 843-846
94. Chang J., et al. Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. J Clin Oncol 17 10 (1999) 3058-3063
95. Potti A., and George D.J. Tyrosine kinase inhibitors in renal cell carcinoma. Clin Cancer Res 10 18 Pt 2 (2004) 6371S-6376S